Clinical Trials Logo

Clinical Trial Summary

This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have undetectable HBV DNA in serum by real-time polymerase chain reaction (PCR) assay.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05355467
Study type Interventional
Source Mylan (Taiwan) Ltd
Contact
Status Completed
Phase Phase 4
Start date August 21, 2019
Completion date July 13, 2021

See also
  Status Clinical Trial Phase
Completed NCT03329820 - Quality of Life and Health Utility of Patients With CHB Infections N/A
Recruiting NCT04030039 - Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Recruiting NCT03210506 - The Changes of Cytokines During Antiviral Therapy N/A
Recruiting NCT03209037 - The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210467 - The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03208998 - The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03209011 - The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210493 - The Changes of Treg Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Recruiting NCT03587467 - Study on Gut Microbiota in Chronic HBV Infected Patients
Recruiting NCT04135235 - Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B